Mechanisms of action of tasquinimod on the tumour microenvironment E. RaymondA. DalgleishR. Pili Review Article Open access 27 October 2013 Pages: 1 - 8
Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer Eun Kyung ChoJi-Young ParkJin-Hyoung Kang Original Article 12 December 2013 Pages: 9 - 16
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001) Yoshihiro HattoriMiyako SatouchiShunichi Negoro Original Article 20 October 2013 Pages: 17 - 23
Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice Hue Jung ParkJennifer A. StokesTony L. Yaksh Original Article 27 October 2013 Pages: 25 - 34
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma Sheeba K. ThomasAlexander SuvorovOlga S. Samoylova Original Article 23 October 2013 Pages: 35 - 42
Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients Jan Nyrop JakobsenEric Santoni-RugiuJens Benn Sørensen Original Article 13 November 2013 Pages: 43 - 51
Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma Hitoshi AndoAtsushi NatsumeToshishiko Wakabayashi Original Article 20 October 2013 Pages: 53 - 60
Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study Anne FloquetAdélaïde DoussauSimone Mathoulin-Pélissier Original Article 20 October 2013 Pages: 61 - 68
Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production Lei GongBo YangGao-jue Wu Original Article 05 November 2013 Pages: 69 - 77
Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies Wei-qun XuLing-yan ZhangYong-min Tang Original Article 25 October 2013 Pages: 79 - 86
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer D. de WitH. GelderblomN. P. van Erp Original Article 23 October 2013 Pages: 87 - 96
Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer Hiroki YamaueSohei SatoiTetsuhiko Shirasaka Original Article 22 October 2013 Pages: 97 - 102
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma J. F. GrippoW. ZhangA. Daud Original Article 01 November 2013 Pages: 103 - 111
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction M. JoergerA. D. R. HuitemaS. Gillessen Original Article 29 October 2013 Pages: 113 - 124
Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients Jung Yong HongEun Mi NamYoung Suk Park Original Article 27 October 2013 Pages: 125 - 130
Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer Jan Nyrop JakobsenEric Santoni-RugiuJens Benn Sørensen Original Article 11 December 2013 Pages: 131 - 137
Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101) Yoon-Koo KangJeong Hwan YookByung Sik Kim Original Article 27 October 2013 Pages: 139 - 149
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma Charles S. HarmonSamuel E. DePrimoRobert J. Motzer Original Article Open access 13 November 2013 Pages: 151 - 161
A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer Young Saing KimSun Jin SymDong Bok Shin Original Article 08 November 2013 Pages: 163 - 169
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer Taofeek K. OwonikokoJoseph AisnerJoan H. Schiller Original Article 28 November 2013 Pages: 171 - 180
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) Ana M. MolinaThomas E. HutsonM. Dror Michaelson Original Article Open access 05 November 2013 Pages: 181 - 189
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer Seung Woo YiDae Ryong KangSeung Woo Park Original Article 10 December 2013 Pages: 191 - 198
The effect of chemotherapy with cisplatin and pemetrexed for choroidal metastasis of non-squamous cell carcinoma Chih-Jen YangYing-Ming TsaiMing-Shyan Huang Original Article 08 November 2013 Pages: 199 - 205
Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers Hussein TawbiSusan M. ChristnerJan H. Beumer Short Communication 30 October 2013 Pages: 207 - 211
Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors Yi-Lin ChiuPatricia LoRussoDawn M. Carlson Short Communication Open access 16 November 2013 Pages: 213 - 217